Formulation optimization of long-acting depot injection of aripiprazole by using D-optimal mixture design

PDA Journal of Pharmaceutical Science and Technology

Volumn 63, Issue 2, 2009, Pages 113-122

  Nahata, Tushar ^a   Saini, T R ^a  

^a SHRI G S INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Aripiprazole; Cholesterol; D optimal design; In situ implant; PLGA

Indexed keywords

ARIPIPRAZOLE; CHOLESTEROL; ETHYLENE OXIDE; POLYGLACTIN; LACTIC ACID; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; D OPTIMAL MIXTURE DESIGN; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL DESIGN; GAMMA RADIATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RADIATION STERILIZATION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; CHEMISTRY; INJECTION; INSTRUMENT STERILIZATION; METHODOLOGY; PHARMACEUTICS; SOLUBILITY;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; INJECTIONS; LACTIC ACID; MALE; PIPERAZINES; POLYGLYCOLIC ACID; QUINOLONES; RATS; RESEARCH DESIGN; SOLUBILITY; STERILIZATION; TECHNOLOGY, PHARMACEUTICAL;

EID: 68349100113     PISSN: 10797440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cheng, Y. H.; Illum, L.; Davis, S. S. Schizophrenia and drug delivery system. J. Drug Target. 2000, 8 (2), 107-17.
2. Wang, L.; Kleiner, L.; Venkatraman, S. Structure formation in injectable poly (lactide-co-glycolide) depots. J. Controlled Release 2003, 90, 345-54.
3. David, A. S.; Adams, C. Depot antipsychotic medication therapy in the treatment of patients with schizophrenia: (1) Meta review; (2) Patient and nurse attitudes. Health Technology Assessment 2001, 5 (34).
4. Gilbert, P. L.; Harris, M. J.; McAdams, L. A.; Jeste, D. V. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch. Gen. Psychiatry 1995, 52 (3), 173-188.
5. Swainston Harrison, T.; Perry, C. M. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004, 64 (15), 1715-1736.
6. Uzun S.; Kozumplik, O.; Mimica, N.; Folnegovic-Smalc, V. Aripiprazole: an overview of a novel antipsychotic. Psychiatr. Danub. 2005, 17 (1-2), 67-75.
7. Haglund, B. O.; Joshi, R.; Himmelstein, K. J. An in situ gelling system for parenteral delivery. J. Controlled Release 1996, 41 (3), 229-235.
8. Kranz, H.; Bodmier, R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm. 2007, 332 (1-2), 107-114.
9. Domb, A. J.; Shikanov, A. Poly(sebacic acid-coricinoleic acid) biodegradable injectable in situ gelling polymer. Biomacromolecules 2006, 7 (1), 288-296.
10. Prabhu, S.; Tran, L. P.; Betageri, G. V. Effect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implants. Drug Deliv. 2005, 12 (6), 393-398.
11. Al-Tahami, K.; Meyer, A.; Singh, J. Poly lactic acid based injectable delivery systems for controlled release of a model protein, lysozyme. Pharm. Dev. Technol. 2006, 11, 79-86.
12. Dong, W. Y.; Guo, Y. Z.; Qui, K. Y.; Gu, Z. W.; Feng, X. D. In vitro degradation and controlled release behaviour of D,L-PLGA50 and PCL-b-D,L-PLGA50 copolymer microspheres. J. Controlled Release 2005, 107 (1), 53-64.
13. Chandrashekar, G.; Udupa, N. Biodegradable injectable implant systems for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. J. Pharm. Pharmacol. 1996, 48 (7), 669-674.
14. Davis, S. S.; Ilum, L. Polymeric microspheres as drug carriers. Biomaterials 1988, 9 (1), 111-115.
15. Shive, M. S.; Anderson, J. M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 1997, 28 (1), 5-24.
16. Yamaguchi, K.; Anderson, J. M. In vivo compatibility of Medisorb 65/35 D-L-Lactide/Glycolide copolymer microspheres. J. Controlled Release 1993, 24, 81-93.
17. Parikh, R. H.; Parikh, J. R.; Dubey, R. R.; Soni, H. N.; Kapadia, K. N. Poly(D,L-lactide-co-glycolide) microspheres containing 5-fluorouracil: optimization of process parameters. AAPS PharmSciTech 2003, 4 (2), E13.
18. El-Malah, Y.; Nazzal, S.; Khanfar, N. M. Doptimal mixture design: optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms. Drug Dev. Ind. Pharm. 2006, 32 (10), 1207-1218.
19. Mura, P.; Furlanetto, S.; Cirri, M.; Maestrelli, F.; Marras, A. M.; Pinzauti, S. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. J. Pharm. Biomed. Res. 2005, 37 (1), 65-71.
20. Pean, J. M.; Venier-Julienne, M. C.; Filmon, R.; Sergent, M.; Phan-Tan-Luu, R.; Benoit, J. P. Optimization of HSA and NGF encapsulation yields in PLGA microparticles. Int. J. Pharm. 1998, 166 (1), 105-115.
21. Indian Pharmacopoeia. Government of India, Ministry of Health and Family Welfare, Controller of Publications: Delhi, 1996; A-24.
22. Shimokawa, Y.; Akiyama, H.; Kashiyama, E.; Koga, T.; Miyamoto, G. High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: Application to the pharmacokinetic study. J. Chromatogr., B 2005, 821 (1), 8-14.
23. Impurities: guideline for residual solvents Q3 C (R3) ICH guidelines (http://www.ich.org/LOB/media/MEDIA423.pdf).
24. Dimethyl sulfoxide (DMSO): A "new" clean, unique, superior solvent. American Chemical Society annual meeting; Washington, DC, August 20-24, 2000 (www.gaylordchemical.com/bulletins/Vignes-ACS.pdf).
25. Mottu, F.; Laurent, A.; Rugenacht, D. A.; Doelker, E. Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J. Pharm. Sci. Technol. 2000, 54 (6), 456-469.